SPHINX

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SPHINX是新一代SPRK1抑制剂。

SPHINX is a new generation inhibitor of SPRK1.

SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2.SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines. Western Blot Analysis Cell Line:ARPE-19 cell line Concentration:10 μM Incubation Time:2 hours Result:Blocked EGF-induced phosphorylation of SRSF1 and SRSF2.

SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo.SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats. Animal Model:C57/B6 mice with laser-induced CNV Dosage:10 ng Administration:Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 Result:Significantly reduced neovascular growth compared with saline-injected controls.Animal Model:Norway Brown rats with laser-induced choroidal neovascularization Dosage:25 ng (10 ng/uL)Administration:Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 Result:Significantly reduced the CNV area compared with saline injected controls.

——

Others

Other Targets

SPRK1

——

——

848057-98-7

354.32

C17H17F3N2O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (141.12 mM)

O=C(C1=CC=C(C)O1)NC2=CC(C(F)(F)F)=CC=C2N3CCOCC3

——

(-20℃)

With Ice Pack

≥ 2 years